Korea Research Institute of Bioscience and Biotechnology

The Catholic University of Korea Industry-academic Cooperation Foundation

Jong Young Choi

Eun Kyung Kim

Sung Hwan Park

Young Il Yeom

Mi La Cho

Kyung Chan Park

Hyang-Sook Yoo

Min Jung Park

Yejin Jang

Joo Yeon Jhun

Jung Ju Lee

Chul Woo Yang

In Young Park

Suk-Jin Yang

Seon Yeong Lee

Jae Kyung Kim

Bo Hwa Sohn

Eun Jung Lee

Sun Woo Lim

Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

Composition for alleviating nephrotoxicity caused by immunosuppressive drug, comprising metformin, and composition for preventing or treating immune disease, comprising the same

The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.

Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP promoter and treatment of cancers by regulating its epigenetic status

Growing community of inventors

Seoul, South Korea

Jong Young Choi